Diagnosing pancreatic cancer using methylation specific PCR analysis of pancreatic juice

Cancer Biology and Therapy

Volumn 2, Issue 1, 2003, Pages 78-83

  Fukushima, Noriyoshi ^a   Walter, Kimberly M ^a   Ueki, Takashi ^a   Sato, Norihiro ^a   Matsubayashi, Hiroyuki ^a   Cameron, John L ^a   Hruban, Ralph H ^a   Canto, Marcia ^a   Yeo, Charles J ^a   Goggins, Michael ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Methylation; Pancreatic adenocarcinoma; Pancreatic juice; ppENK

Indexed keywords

DNA; ENKEPHALIN; PREPROENKEPHALIN; PRIMER DNA; PROTEIN P16INK4A; PROTEIN PRECURSOR;

ADULT; AGED; ARTICLE; CHEMISTRY; COLLOID CARCINOMA; COMPARATIVE STUDY; DNA METHYLATION; DUODENUM; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PANCREAS; PANCREAS CARCINOMA; PANCREAS DISEASE; PANCREAS TUMOR; PATHOLOGY; POLYMERASE CHAIN REACTION; SECRETION;

ADENOCARCINOMA, MUCINOUS; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, INTRADUCTAL, NONINFILTRATING; CARCINOMA, PANCREATIC DUCTAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; DUODENUM; ENKEPHALINS; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREAS; PANCREATIC DISEASES; PANCREATIC NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEIN PRECURSORS;

EID: 0037484547     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999; 117:1464-84.
2. DiMagno EP, Reber HA, Tempero MA. AGA technical review on the epidemiology, diagnosis, and treatment of pancreatic ductal adenocarcinoma. American Gastroenterological Association. Gastroenterology 1999; 117:1464-84.
3. Sohn TA, Yeo CJ, Cameron JL, Koniaris L, Kaushal S, Abrams RA, Sauter PK, Coleman J, Hruban RH, Lillemoe KD. Resected adenocarcinoma of the pancreas-616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000; 4:567-79.
4. Yamaguchi Y, Watanabe H, Yrdiran S, Ohtsubo K, Motoo Y, Okai T, Sawabu N. Detection of mutations of p53 tumor suppressor gene in pancreatic juice and its application to diagnosis of patients with pancreatic cancer: comparison with K-ras mutation. Clin Cancer Res 1999; 5:1147-53. (Pubitemid 29233231)
5. Seki K, Suda T, Aoyagi Y, Sugawara S, Natsui M, Motoyama H, et al. Diagnosis of pancreatic adenocarcinoma by detection of human telomerase reverse transcriptase messenger RNA in pancreatic juice with sample qualification. Clin Cancer Res 2001; 7:1976-81. (Pubitemid 32994834)
6. Uehara H, Nakaizumi A, Tatsuta M, Baba M, Takenaka A, Uedo N, et al. Diagnosis of pancreatic cancer by detecting telomerase activity in pancreatic juice: comparison with K-ras mutations. Am J Gastroenterol 1999; 94:2513-8. (Pubitemid 29420682)
7. Rosty C, Goggins M. Early detection of pancreatic carcinoma. Hematol Oncol Clin North Am 2002; 16:37-52. (Pubitemid 34578625)
8. Tersmette AC, Petersen GM, Offerhaus GJ, Falatko FC, Brune KA, Goggins M, et al. Increased risk of incident pancreatic cancer among first-degree relatives of patients with familial pancreatic cancer. Clin Cancer Res 2001; 7:738-44. (Pubitemid 32708001)
9. Brentnall TA, Bronner MP, Byrd DR, Haggitt RC, Kimmey MB. Early diagnosis and treatment of pancreatic dysplasia in patients with a family history of pancreatic cancer. Ann Intern Med 1999; 131:247-55. (Pubitemid 29383653)
10. Murphy KM, Brune KA, Griffin C, Sollenberger JE, Petersen GM, Bansal R, et al. Evaluation of Candidate Genes MAP2K4, MADH4, ACVR1B, and BRCA2 in Familial Pancreatic Cancer: Deleterious BRCA2 Mutations in 17%. Cancer Res 2002; 62:3789-93. (Pubitemid 34728862)
11. Esteller M, Corn PG, Baylin SB, Herman JG. A gene hypermethylation profile of human cancer. Cancer Res 2001; 61:3225-9. (Pubitemid 32695003)
12. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev Genet 2002; 3:415-28. (Pubitemid 34587077)
13. Dominguez G, Carballido J, Silva J, Silva JM, Garcia JM, Menendez J, et al. p14ARF Promoter Hypermethylation in Plasma DNA as an Indicator of Disease Recurrence in Bladder Cancer Patients. Clin Cancer Res 2002; 8:980-5. (Pubitemid 35177345)
14. Esteller M, Sanchez-Cespedes M, Rosell R, Sidransky D, Baylin SB, Herman JG. Detection of aberrant promoter hypermethylation of tumor suppressor genes in serum DNA from non-small cell lung cancer patients. Cancer Res 1999; 59:67-70. (Pubitemid 29062958)
15. Cairns P, Esteller M, Herman JG, Schoenberg M, Jeronimo C, Sanchez-Cespedes M, et al. Molecular detection of prostate cancer in urine by GSTP1 hypermethylation. Clin Cancer Res 2001; 7:2727-30. (Pubitemid 32911377)
16. Chan MW, Chan LW, Tang NL, Tong JH, Lo KW, Lee TL, et al. Hypermethylation of multiple genes in tumor tissues and voided urine in urinary bladder cancer patients. Clin Cancer Res 2002; 8:464-70. (Pubitemid 34193966)
17. Belinsky SA, Palmisano WA, Gilliland FD, Crooks LA, Divine KK, Winters SA, et al. Aberrant promoter methylation in bronchial epithelium and sputum from current and former smokers. Cancer Res 2002; 62:2370-7. (Pubitemid 34411720)
18. Evron E, Dooley WC, Umbricht CB, Rosenthal D, Sacchi N, Gabrielson E, et al. Detection of breast cancer cells in ductal lavage fluid by methylation-specific PCR. Lancet 2001; 357:1335-6. (Pubitemid 32441534)
19. Ueki T, Toyota M, Sohn T, Yeo CJ, Issa JP, Hruban RH, et al. Hypermethylation of multiple genes in pancreatic adenocarcinoma. Cancer Res 2000; 60:1835-9. (Pubitemid 30207640)
20. Ueki T, Toyota M, Skinner H, Walter KM, Yeo CJ, Issa JP, et al. Identification and characterization of differentially methylated CpG islands in pancreatic carcinoma. Cancer Res 2001; 61:8540-6.
21. Jansen J, Fukushima N, Rosty C, Walter K, Altink R, van Keen T, et al. Aberrant methylation of the 5′ CpG island f tSLC1 is common in pancreatic ductal adenocarcinoma and is first manifest in high-grade PanINs. Cancer Biol Ther 2002; 1:293-6.
22. Matsubayashi H, Sato N, Fukushima N, Yeo CH, Walter KM, Brune K, et al. methylation of cyclin D2 is frequently observed in pancreatic cancer but is also an age-related phenomenon in gastrointestinal tissue. Clin Cancer Res: in press.
23. Zagon IS, Smith JP, Conter R, McLaughlin PJ. Identification and characterization of opioid growth factor receptor in human pancreatic adenocarcinoma. Int J Mol Med 2000; 5:77-84.
24. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999; 14:577-84.
25. Fukushima N, Sato N, Ueki T, Rosty C, Walter KM, Wilentz RE, et al. Aberrant methylation of preproenkephalin and p16 genes in pancreatic intraepithelial neoplasia and pancreatic ductal adenocarcinoma. Am J Pathol 2002; 160:1573-81. (Pubitemid 34525637)
26. Sato N, Ueki T, Fukushima N, Iacobuzio-Donahue CA, Yeo CJ, Cameron JL, et al. Aberrant methylation of CpG islands in intraductal papillary mucinous neoplasms of the pancreas. Gastroenterology 2002; 123:365-72. (Pubitemid 34747556)
27. Tanaka M, Yokohata K, Konomi H, Yamaguchi K, Chijiiwa K, Ohta M. Segmental balloon cytology for preoperative localization of in situ pancreatic cancer. Gastrointest Endosc 1997; 46:447-9. (Pubitemid 27498393)
28. Issa JP, Ottaviano YL, Celano P, Hamilton SR, Davidson NE, Baylin SB. Methylation of the oestrogen receptor CpG island links ageing and neoplasia in human colon. Nat Genet 1994; 7:536-40. (Pubitemid 24308343)
29. Waki T, Tamura G, Tsuchiya T, Sato K, Nishizuka S, Motoyama T. Promoter methylation status of E-cadherin, hMLH1, and p16 genes in nonneoplastic gastric epithelia. Am J Pathol 2002; 161:399-403. (Pubitemid 36142148)
30. Matsubayashi H, Sato N, Fukushima N, Yeo C, Walter K, Sahin F, et al. High frequency of cyclin D2 methylation in pancreatic carcinoma. Clin Cancer Res: in press.
31. Nakagawa H, Nuovo GJ, Zervos EE, Martin EW, Jr., Salovaara R, Aaltonen LA, et al. Age-related hypermethylation of the 5′ region of MLH1 in normal colonic mucosa is associated with microsatellite-unstable colorectal cancer development. Cancer Res 2001; 61:6991-5. (Pubitemid 32946483)
32. Nguyen C, Liang G, Nguyen TT, Tsao-Wei D, Groshen S, Lubbert M, et al. Susceptibility of nonpromoter CpG islands to de novo methylation in normal and neoplastic cells. J Natl Cancer Inst 2001; 93:1465-72. (Pubitemid 32982675)
33. Suzuki H, Gabrielson E, Chen W, Anbazhagan R, van Engeland M, Weijenberg MP, et al. A genomic screen for genes upregulated by demethylation and histone deacetylase inhibition in human colorectal cancer. Nat Genet 2002; 31:141-9.
34. Costello JF, Fruhwald MC, Smiraglia DJ, Rush LJ, Robertson GP, Gao X, et al. Aberrant CpG-island methylation has non-random and tumour-type-specific patterns. Nat Genet 2000; 24:132-8.
35. Millar DS, Warnecke PM, Melki JR, Clark SJ. Methylation sequencing from limiting DNA: embryonic, fixed, and microdissected cells. Methods 2002; 27:108-13. (Pubitemid 34757120)
36. Canto MI WL, Goggins M, Petersen G, Brune K, Yeo C, Giardiello F, et al.Screening for pancreatic neoplasia in high-risk individuals: The Johns Hopkins Experience. American Gastroenterology Annual Meeting (Abstract ID: 105494) 2002.
37. Fukushima N, Mukai K. Pancreatic neoplasms with abundant mucus production: emphasis on intraductal papillary-mucinous tumors and mucinous cystic tumors. Adv Anat Pathol 1999; 6:65-77.
38. Sohn TA, Yeo CJ, Cameron JL, Iacobuzio-Donahue CA, Hruban RH, Lillemoe KD. Intraductal papillary mucinous neoplasms of the pancreas: an increasingly recognized clinicopathologic entity. Ann Surg 2001; 234:313-21; discussion 321-2.